



Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference

November 6, 2018

BOULDER, Colo., Nov. 6, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website.

Event: Stifel 2018 Healthcare Conference
Presenter: Ron Squarer, Chief Executive Officer, Array BioPharma
Date: Tuesday, November 13, 2018
Time: 3:30 p.m. Eastern Time
Webcast: <http://wsw.com/webcast/stifel14/array/>

Event: Jefferies 2018 London Healthcare Conference
Presenter: Ron Squarer, Chief Executive Officer, Array BioPharma
Date: Thursday, November 15, 2018
Time: 9:00 a.m. Eastern Time
Webcast: <http://wsw.com/webcast/jeff115/array/>

About Array BioPharma

Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets in the United States BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a *BRAF*^{V600E} or *BRAF*^{V600K} mutation. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in *BRAF*-mutant colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), larotrectinib and LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Ganovo® (danoprevir, partnered with Roche) was recently approved in China for the treatment of viral hepatitis C. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.

CONTACT:

Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
ir@arraybiopharma.com



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-stifel-2018-healthcare-conference-and-the-jefferies-2018-london-healthcare-conference-300744231.html>

SOURCE Array BioPharma Inc.